Send to

Choose Destination
Clin Orthop Surg. 2018 Mar;10(1):33-40. doi: 10.4055/cios.2018.10.1.33. Epub 2018 Feb 27.

Analgesic Efficacy and Safety of Prolonged-Release Oxycodone/Naloxone in Korean Patients with Chronic Pain from Spinal Disorders.

Author information

Department of Orthopaedic Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Department of Orthopaedic Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Orthopaedic Surgery, Dong-A University Hospital, Busan, Korea.
Department of Orthopaedic Surgery, SMG-SNU Boramae Medical Center, Seoul National University College of Medicine, Seoul, Korea.
Department of Orthopaedic Surgery, Yonsei University College of Medicine, Seoul, Korea.
Department of Orthopedic Surgery, Seoul Spine Institute, Inje University Sanggye Paik Hospital, Seoul, Korea.
Department of Orthopaedic Surgery, Inha University Hospital, Incheon, Korea.
Department of Orthopaedic Surgery, Chungnam National University Hospital, Daejeon, Korea.
Department of Orthopaedic Surgery, Chungbuk National University Hospital, Cheongju, Korea.
Department of Orthopaedic Surgery, Guri Hospital, Hanyang University College of Medicine, Guri, Korea.
Mundipharma Korea Ltd., Seoul, Korea.



A prolonged-release formulation of oxycodone/naloxone has been shown to be effective in European populations for the management of chronic moderate to severe pain. However, no clinical data exist for its use in Korean patients. The objective of this study was to assess efficacy and safety of prolonged-release oxycodone/naloxone in Korean patients for management of chronic moderate-to-severe pain.


In this multicenter, single-arm, open-label, phase IV study, Korean adults with moderate-to-severe spinal disorder-related pain that was not satisfactorily controlled with weak opioids and nonsteroidal anti-inflammatory drugs received prolonged-release oral oxycodone/naloxone at a starting dose of 10/5 mg/day (maximum 80/40 mg/day) for 8 weeks. Changes in pain intensity and quality of life (QoL) were measured using a numeric rating scale (NRS, 0-10) and the Korean-language EuroQol-five dimensions questionnaire, respectively.


Among 209 patients assessed for efficacy, the mean NRS pain score was reduced by 25.9% between baseline and week 8 of treatment (p < 0.0001). There was also a significant improvement in QoL from baseline to week 8 (p < 0.0001). The incidence of adverse drug reactions was 27.7%, the most common being nausea, constipation, and dizziness; 77.9% of these adverse drug reactions had resolved or were resolving at the end of the study.


Prolonged-release oxycodone/naloxone provided significant and clinically relevant reductions in pain intensity and improved QoL in Korean patients with chronic spinal disorders. ( identifier: NCT01811238).


Analgesia; Chronic pain; Oxycodone naloxone combination; Spine

[Indexed for MEDLINE]
Free PMC Article

Conflict of interest statement

CONFLICT OF INTEREST: HJP is an employee of Mundipharma Korea Ltd. Medical writing and editorial support was provided by Rhian Harper Owen (Complete Medical Communications Ltd.) and by Tech Observer Asia-Pacific Pte. Ltd. This support was funded by Mundipharma Korea Ltd. No other potential conflict of interest relevant to this article was reported.

Supplemental Content

Full text links

Icon for The Korean Orthopaedic Association Icon for PubMed Central
Loading ...
Support Center